Table 2.

Details of the clinical, biological and treatment data collected during each follow-up visit

	Month 0	Month 3	Month 6	Month 12
Patients attending the visit	78 (100%)	42 (65.6%)	54 (84.4%)	38 (59.4%)
Serum urate (mg/dL)	7.43 ± 2.33	6.57 ± 1.9	5.59 ± 1.56	5.63 ± 1.81
Ongoing ULT	36 (46.2%)	33 (78.5%)	47 (87.1%)	34 (89.4%)
Ongoing flare prophylaxis	25 (32.1%)	20 (47.6%)	27 (50%)	16 (42.1%)
Number of flares since M0	N/A	0.6 ± 1.3	0.7 ± 1.4	1.5 ± 3.3
Patients with at least 1 flare since M0	N/A	15 (35.7%)	19 (35.2%)	16 (42.1%)
Number of flares since previous visit	N/A	0.6 ± 1.3	0.3 ± 0.7	0.7 ± 1.6
Patients with at least 1 flare since previous visit	N/A	15 (35.7%)	9 (17%)	12 (31.6%)

M0 month 0, ULT urate lowering therapy